19205-Leukemia-CLL-519

Leukemia

ULTRA-V: Phase 2 Study to Assess the Efficacy and Safety of Ublituximab in Combination with Umbralisib and Venetoclax (U2-V) in Subjects with Chronic Lymphocytic Leukemia (CLL)(U2-VEN-207)

  • Details

ClinicalTrials.gov ID: NCT03801525
Diagnosis Type: CLL
USOR Number: 19205

  • Address

1105 Central Expressway, Suite 320
Allen, TX 75013
P: (469) 467-4392

Find a Clinical Trial

Search by practice name, trial titles, indicators and specific disease types.